Dunad Therapeutics

Dunad Therapeutics Focuses on Developing Next-Generation Targeted Protein Degradation Therapies. Dunad's platform achieves selective degradation through direct target modification using tunable monovalent small molecules, opening new target space and enabling the development of more drug-like, orally bioavailable, and CNS-penetrant protein degraders. The company's novel molecular approach is fully tunable, features exquisite selectivity, and is based on a target class-agnostic mechanism of action distinct from other targeted protein degradation technologies. This has the potential to generate orally bioavailable degrader therapies, significantly expanding the frontier of protein degradation targets.